The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors
Open accessAbstract
The baculovirus expression vector system (BEVS) platform has become an established manufacturing platform for the production of viral vaccines and gene therapy vectors. Nine BEVS‐derived products have been approved – four for human use (Cervarix®, Provenge®, Glybera® and Flublok®) and five for veterinary use (Porcilis® Pesti, BAYOVAC CSF E2®, Circumvent® PCV, Ingelvac CircoFLEX® and Porcilis® PCV). The BEVS platform offers many advantages, including manufacturing speed, flexible product design, inherent safety and scalability. This combination of features and product approvals has previously attracted interest from academic researchers, and more recently from industry leaders, to utilize BEVS to develop next generation vaccines, vectors for gene therapy, and other biopharmaceutical complex proteins. In this review, we explore the BEVS platform, detailing how it works, platform features and limitations and important considerations for manufacturing and regulatory approval. To underscore the growth in opportunities for BEVS‐derived products, we discuss the latest product developments in the gene therapy and influenza vaccine fields that follow in the wake of the recent product approvals of Glybera® and Flublok®, respectively. We anticipate that the utility of the platform will expand even further as new BEVS‐derived products attain licensure. Finally, we touch on some of the areas where new BEVS‐derived products are likely to emerge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Garten, R. J., Davis, C. T., Russell, C. A., Shu, B., Lindstrom, S., Balish, A., Sessions, W. M., Xu, X., Skepner, E., Deyde, V., et al. (2009) · Science · doi:10.1126/science.1176225 · Cited by 2,499
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
The establishment of two cell lines from the insectspodoptera frugiperda (lepidoptera; noctuidae)
Vaughn, J. L., Goodwin, R. H., Tompkins, G. J., & McCawley, P. (1977) · In Vitro · doi:10.1007/bf02615077 · Cited by 1,222
Production of recombinant proteins by microbes and higher organisms
Demain, A. L., & Vaishnav, P. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.01.008 · Cited by 1,028
Baculovirus as versatile vectors for protein expression in insect and mammalian cells
Kost, T. A., Condreay, J. P., & Jarvis, D. L. (2005) · Nature Biotechnology · doi:10.1038/nbt1095 · Cited by 1,014
Production of human beta interferon in insect cells infected with a baculovirus expression vector.
Smith, G. E., Summers, M. D., & Fraser, M. J. (1983) · Molecular and Cellular Biology · doi:10.1128/mcb.3.12.2156 · Cited by 968
The Complete DNA Sequence of Autographa californica Nuclear Polyhedrosis Virus
Ayres, M. D., Howard, S. C., Kuzio, J., Lopez-Ferber, M., & Possee, R. D. (1994) · Virology · doi:10.1006/viro.1994.1380 · Cited by 963
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Influenza vaccine: The challenge of antigenic drift
CARRAT, F., & FLAHAULT, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 708
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696
Song, D., & Park, B. (2012) · Virus Genes · doi:10.1007/s11262-012-0713-1 · Cited by 677
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
Efficient gene transfer into human hepatocytes by baculovirus vectors.
Hofmann, C., Sandig, V, Jennings, G., Rudolph, M., Schlag, P., & Strauss, M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.22.10099 · Cited by 492
Baculovirus-mediated gene transfer into mammalian cells.
Boyce, F. M., & Bucher, N. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2348 · Cited by 464
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
Skowronski, D. M., Janjua, N. Z., De Serres, G., Sabaiduc, S., Eshaghi, A., Dickinson, J. A., Fonseca, K., Winter, A.-L., Gubbay, J. B., Krajden, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092153 · Cited by 416
Traditional and New Influenza Vaccines
Wong, S.-S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 372
A method for producing recombinant baculovirus expression vectors at high frequency.
Kitts, P. A., & Possee, R. D. (1993) · PubMed · Cited by 350
Thirty years of baculovirus–insect cell protein expression: from dark horse to mainstream technology
van Oers, M. M., Pijlman, G. P., & Vlak, J. M. (2015) · Journal of General Virology · doi:10.1099/vir.0.067108-0 · Cited by 348
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Coleman, C. M., Liu, Y. V., Mu, H., Taylor, J. K., Massare, M., Flyer, D. C., Glenn, G. M., Smith, G. E., & Frieman, M. B. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.016 · Cited by 293
Bright, R. A., Carter, D. M., Daniluk, S., Toapanta, F. R., Ahmad, A., Gavrilov, V., Massare, M., Pushko, P., Mytle, N., Rowe, T., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.106 · Cited by 288
Wickham, T. J., Davis, T. R., Granados, R. R., Shuler, M. L., & Wood, H. A. (1992) · Biotechnology Progress · doi:10.1021/bp00017a003 · Cited by 285
Smith, R. H., Levy, J. R., & Kotin, R. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.128 · Cited by 261
Recombinant protein vaccines produced in insect cells
Cox, M. M. J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.016 · Cited by 223
Chapter 14 Baculovirus–Insect Cell Expression Systems
Jarvis, D. L. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(09)63014-7 · Cited by 219
Recombinant Adeno-associated Virus Transduction and Integration
Schultz, B. R., & Chamberlain, J. S. (2008) · Molecular Therapy · doi:10.1038/mt.2008.103 · Cited by 215
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome
Hui, D. S., Memish, Z. A., & Zumla, A. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000046 · Cited by 209
Josefsberg, J. O., & Buckland, B. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24493 · Cited by 201
Baculovirus as a highly efficient expression vector in insect and mammalian cells
HU, Y.-C. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00078.x · Cited by 173
Wei, X., Ju, X., Yi, X., Zhu, Q., Qu, N., Liu, T., Chen, Y., Jiang, H., Yang, G., Zhen, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029500 · Cited by 172
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166
Opportunities and challenges for the baculovirus expression system
van Oers, M. M. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.001 · Cited by 165
Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells
Metz, S. W., Gardner, J., Geertsema, C., Le, T. T., Goh, L., Vlak, J. M., Suhrbier, A., & Pijlman, G. P. (2013) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002124 · Cited by 163
Adeno-associated virus (AAV) gene therapy for neurological disease
Weinberg, M. S., Samulski, R. J., & McCown, T. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.004 · Cited by 162
Grieger, J. C., & Samulski, R. J. (2005) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_005 · Cited by 159
Treanor, J. J., Sahly, H. M. E., King, J. C., Graham, I. L., Izikson, R., Kohberger, R. C., PATRIARCA, P. A., & Cox, M. M. J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.128 · Cited by 158
Current advancements and potential strategies in the development of MERS-CoV vaccines
Zhang, N., Jiang, S., & Du, L. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.912134 · Cited by 158
Heikkinen, T., Ikonen, N., & Ziegler, T. T. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu664 · Cited by 151
Successful Production of Pseudotyped rAAV Vectors Using a Modified Baculovirus Expression System
Kohlbrenner, E., Aslanidi, G., Nash, K. R., Shklyaev, S., Campbell‐Thompson, M., Byrne, B. J., Snyder, R. O., Muzyczka, N., Warrington, K. H., & Zolotukhin, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.018 · Cited by 142
He, Y., Li, J., Heck, S., Lustigman, S., & Jiang, S. (2006) · Journal of Virology · doi:10.1128/jvi.00083-06 · Cited by 135
López-Macías, C. I. R., Ferat-Osorio, E. A., Tenorio-Calvo, A. V., Isibasi, A., Talavera, J. O., Arteaga-Ruiz, O., Arriaga‐Pizano, L., Hickman, S. P., Allende, M. C., Lenhard, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.099 · Cited by 135
Deschuyteneer, M., Elouahabi, A., Plainchamp, D., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.5.11023 · Cited by 132
Identification of a Novel Rhabdovirus in Spodoptera frugiperda Cell Lines
Ma, H., Galvin, T. A., Glasner, D. R., Shaheduzzaman, S., & Khan, A. S. (2014) · Journal of Virology · doi:10.1128/jvi.00780-14 · Cited by 125
Insect cell technology is a versatile and robust vaccine manufacturing platform
Mena, J. A., & Kamen, A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.24 · Cited by 124
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Receptor Specificity and Transmission of H2N2 Subtype Viruses Isolated from the Pandemic of 1957
Pappas, C., Viswanathan, K., Chandrasekaran, A., Raman, R., Katz, J. M., Sasisekharan, R., & Tumpey, T. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011158 · Cited by 118
Krammer, F., Palese, P., & Steel, J. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_408 · Cited by 117
Pijlman, G. P., van Schijndel, J. E., & Vlak, J. M. (2003) · Journal of General Virology · doi:10.1099/vir.0.19438-0 · Cited by 107
Salmon, F., Grosios, K., & Petry, H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 106
Chikungunya at the Door — Déjà Vu All Over Again?
Morens, D. M., & Fauci, A. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1408509 · Cited by 106
A transgenic insect cell line engineered to produce CMP-sialic acid and sialylated glycoproteins
Aumiller, J. J. (2003) · Glycobiology · doi:10.1093/glycob/cwg051 · Cited by 101
Lu, B., Huang, Y. P., Huang, L., Bao, L., Zheng, Z., Chen, Z., Chen, J., Hu, Q., & Wang, H. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03231.x · Cited by 97
SweetBac: A New Approach for the Production of Mammalianised Glycoproteins in Insect Cells
Palmberger, D., Wilson, I. B. H., Berger, I., Grabherr, R. M., & Rendić, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034226 · Cited by 97
Urabe, M., Xin, K.-Q., Obara, Y., Nakakura, T., Mizukami, H., Kume, A., Okuda, K., & Ozawa, K. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.024 · Cited by 94
Development of the Vault Particle as a Platform Technology
Rome, L. H., & Kickhoefer, V. A. (2012) · ACS Nano · doi:10.1021/nn3052082 · Cited by 93
Goji, N. A., Nolan, C., Hill, H., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/590916 · Cited by 92
Zhou, Z., Post, P. L., Chubet, R. G., Holtz, K., McPherson, C. E., Petrić, M., & Cox, M. M. J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.059 · Cited by 89
Treanor, J. J., Essink, B. J., Hull, S. G., Reed, S. G., Izikson, R., PATRIARCA, P. A., Goldenthal, K. L., Kohberger, R. C., & Dunkle, L. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.064 · Cited by 89
Influenza Neuraminidase as a Vaccine Antigen
Eichelberger, M. C., & Wan, H. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_398 · Cited by 83
Buckland, B. C., Boulanger, R., Fino, M., Srivastava, I. K., Holtz, K., Khramtsov, N. V., McPherson, C. E., Meghrous, J., Kubera, P., & Cox, M. M. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.074 · Cited by 81
Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system
Metz, S., & Pijlman, G. P. (2011) · Journal of Invertebrate Pathology · doi:10.1016/j.jip.2011.05.002 · Cited by 80
Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors
Lostal, W., Kodippili, K., Yue, Y., & Duan, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.210 · Cited by 77
Middle East respiratory syndrome coronavirus: transmission and phylogenetic evolution
Al‐Tawfiq, J. A., & Memish, Z. A. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.08.001 · Cited by 76
Current status of haemophilia gene therapy
High, K. A., Nathwani, A. C., Spencer, H. T., & Lillicrap, D. (2014) · Haemophilia · doi:10.1111/hae.12411 · Cited by 74
New developments in the use of gene therapy to treat Duchenne muscular dystrophy
Jarmin, S., Kymäläinen, H., Popplewell, L. J., & Dickson, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.866087 · Cited by 74
Advances in AAV Vector Development for Gene Therapy in the Retina
Day, T. P., Byrne, L. C., Schaffer, D. V., & Flannery, J. G. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_86 · Cited by 73
Virág, T., Cecchini, S., & Kotin, R. M. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.092 · Cited by 73
Keitel, W., Treanor, J. J., Sahly, H. M. E., Gilbert, A., Meyer, A. L., PATRIARCA, P. A., & Cox, M. M. J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.037 · Cited by 64
Lu, X., Chen, Y., Bai, B., Hu, H., Tao, L., Yang, J., Chen, J., Chen, Z., Hú, Z., & Wang, H. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02676.x · Cited by 63
Bai, B., Hu, Q., Hu, H., Zhou, P., Shi, Z., Meng, J., Lu, B., Huang, Y., Mao, P., & Wang, H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002685 · Cited by 59
Caubet, J., & Ponvert, C. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.04.004 · Cited by 58
Negrete, A., Yang, L. C., Mendez, A. F., Levy, J. R., & Kotin, R. M. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1092 · Cited by 56
Wagner, J. M., Pajerowski, J. D., Daniels, C. L., McHugh, P. M., Flynn, J. A., Balliet, J. W., Casimiro, D. R., & Subramanian, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094401 · Cited by 53
Feshchenko, E. A., Rhodes, D. G., Felberbaum, R., McPherson, C. E., Rininger, J. A., Post, P. L., & Cox, M. M. J. (2012) · BMC Biotechnology · doi:10.1186/1472-6750-12-77 · Cited by 49
Self-citationToward exascale production of recombinant adeno-associated virus for gene transfer applications
Cecchini, S., Negrete, A., & Kotin, R. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.61 · Cited by 46
Improving adeno‐associated vector yield in high density insect cell cultures
Mena, J. A., Aucoin, M. G., Montes, J., Chahal, P. S., & Kamen, A. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1420 · Cited by 45
A designer hyper interleukin 11 (H11) is a biologically active cytokine
Dams‐Kozlowska, H., Gryska, K., Kwiatkowska-Borowczyk, E. P., Iżycki, D., Rose‐John, S., & Mackiewicz, A. A. (2012) · BMC Biotechnology · doi:10.1186/1472-6750-12-8 · Cited by 39
Bai, B., Lu, X., Meng, J., Hu, Q., Mao, P., Lu, B., Chen, Z., Yuan, Z., & Wang, H. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.010 · Cited by 38
Okada, T., Ihara, H., Ito, R., Nakano, M., Matsumoto, K., Yamaguchi, Y., Taniguchi, N., & Ikeda, Y. (2010) · Glycobiology · doi:10.1093/glycob/cwq080 · Cited by 31
Feng, Q., Liu, Y., Qu, X., Deng, H., Ding, M., Lau, T. L. T., Yu, A. C., & Chen, J. (2006) · DNA and Cell Biology · doi:10.1089/dna.2006.25.668 · Cited by 30
Mammalian Stable Expression of Biotherapeutics
Jostock, T., & Knopf, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_15 · Cited by 28
Xiao, X., & Dimitrov, D. S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4257-y · Cited by 28
Development of a recombinant toxin fragment vaccine for Clostridium difficile infection
Karczewski, J., Zorman, J. K., Wang, S., Miezeiewski, M., Xie, J., Soring, K. L., Petrescu, I., Rogers, I. T., Thiriot, D. S., Cook, J. C., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.026 · Cited by 27
Holtz, K. M., Robinson, P. S., Matthews, E. E., Hashimoto, Y., McPherson, C. E., Khramtsov, N. V., Reifler, M. J., Meghrous, J., Rhodes, D. G., Cox, M. M. J., et al. (2014) · BMC Biotechnology · doi:10.1186/s12896-014-0111-y · Cited by 24
Gypsy endogenous retrovirus maintains potential infectivity in several species of Drosophilids
Llorens, J. V., Clark, J. B., Martínez‐Garay, I., Soriano, S., de Frutos, R., & Martínez-Sebastián, M. J. (2008) · BMC Evolutionary Biology · doi:10.1186/1471-2148-8-302 · Cited by 23
Chen, X., Liu, H., Zhang, T., Liu, Y., Xie, X.-X., Wang, Z., & Xu, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095448 · Cited by 22
Large-Scale Production of Recombinant Adeno-Associated Viral Vectors
Negrete, A., & Kotin, R. M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-237-3_5 · Cited by 18
Kupferschmidt, K. (2014) · Science · doi:10.1126/science.345.6201.1108 · Cited by 18
Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
Al‐Tawfiq, J. A., & Memish, Z. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416975-3.00014-5 · Cited by 8
Cited by
Tripathi, N. K., & Shrivastava, A. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00420 · Cited by 575
(BIOHAZ), E. P. O. B. H., Ricci, A., Allende, A., Bolton, D., Chemaly, M., Davies, R., Girones, R., Herman, L., Koutsoumanis, K., Lindqvist, R., et al. (2017) · EFSA Journal · doi:10.2903/j.efsa.2017.4664 · Cited by 458
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Production of virus-like particles for vaccines
Fuenmayor, J., Gòdia, F., & Cervera, L. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.07.010 · Cited by 318
Current challenges in biotherapeutic particles manufacturing
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693541 · Cited by 123
Metadata
- Authors
- Felberbaum, R. S.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2015-03-20
- Volume
- 10
- Issue
- 5
- Pages
- 702-714
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2072384527
- Cited by
- 264
- References
- 91
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.